Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing since 12/18/2024, newest first.
| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Evommune, Inc.
13G/A
Amendment 1
EVMN · 30054Y107
|
3.9% |
8/14/2026
Event 6/30/2026
|
|||
| Andera Partners | 3.9% | ||||
| BioDiscovery 6 FPCI | 3.9% | ||||
| Stephane Bergez | 3.9% | ||||
| Francois Xavier Mauron | 3.9% | ||||
|
Inventiva S.A.
13G/A
Amendment 2
IVA · 46124U107
|
7.7% |
2/17/2026
Event 12/31/2025
|
|||
| Andera Partners | 7.7% | ||||
| BioDiscovery 6 FPCI | 7.7% | ||||
| Stephane Bergez | 7.7% | ||||
| Francois Xavier Mauron | 7.7% | ||||
|
Evommune, Inc.
13G
EVMN · 30054Y107
|
6.0% |
11/17/2025
Event 11/7/2025
|
|||
| Andera Partners | 6.0% | ||||
| BioDiscovery 6 FPCI | 6.0% | ||||
| Stephane Bergez | 6.0% | ||||
| Francois Xavier Mauron | 6.0% | ||||
|
Mineralys Therapeutics, Inc.
13G/A
Amendment 1
MLYS · 603170101
|
4.2% |
8/14/2025
Event 6/30/2025
|
|||
| Andera Partners | 4.2% | ||||
| BioDiscovery 6 FPCI | 4.2% | ||||
| Stephane Bergez | 4.2% | ||||
| Francois Xavier Mauron | 4.2% | ||||
|
Inventiva S.A.
13G/A
Amendment 1
IVA · 46124U107
|
8.8% |
8/14/2025
Event 6/30/2025
|
|||
| Andera Partners | 8.8% | ||||
| BioDiscovery 6 FPCI | 8.8% | ||||
| Stephane Bergez | 8.8% | ||||
| Francois Xavier Mauron | 8.8% | ||||
|
Inventiva S.A.
13G
IVA · 46124U107
|
6.5% |
4/14/2025
Event 10/17/2024
|
|||
| Andera Partners | 6.5% | ||||
| BioDiscovery 6 FPCI | 6.5% | ||||
| Stephane Bergez | 6.5% | ||||
| Francois Xavier Mauron | 6.5% | ||||